Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Express Scripts
Chinese Patent Office
Federal Trade Commission
Mallinckrodt
Farmers Insurance
Healthtrust
Deloitte
Cipla

Generated: July 22, 2018

DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

« Back to Dashboard

Summary for Glaxosmithkline Cons
International Patents:315
US Patents:11
Tradenames:11
Ingredients:10
NDAs:15

Drugs and US Patents for Glaxosmithkline Cons

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 OTC Yes Yes 8,940,772 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 OTC Yes Yes 8,501,164 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 021330-001 Oct 31, 2002 OTC Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Glaxosmithkline Cons

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 4,755,534*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 5,681,849*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 5,681,849*PED ➤ Try a Free Trial
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 5,972,916 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 60 mg ➤ Subscribe 2010-09-08
➤ Subscribe Gum 4 mg ➤ Subscribe 2013-01-22
➤ Subscribe Gum 2 mg ➤ Subscribe 2013-01-22

Non-Orange Book US Patents for Glaxosmithkline Cons

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,498,321 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents ➤ Try a Free Trial
6,777,400 Anti-inflammatory androstane derivative compositions ➤ Try a Free Trial
6,787,532 Formulation containing anti-inflammatory androstane derivatives ➤ Try a Free Trial
7,798,368 Fluid dispensing device ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Glaxosmithkline Cons Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C011/2008 Ireland ➤ Try a Free Trial SPC011/2008: 20081105, EXPIRES: 20230110
269 Luxembourg ➤ Try a Free Trial PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0021 Belgium ➤ Try a Free Trial PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
C0042 Belgium ➤ Try a Free Trial PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Cipla
McKesson
Deloitte
Argus Health
Fuji
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.